Chronix Biomedical, Inc., a developer of novel blood-based cancer molecular diagnostics, is pleased to announce that results of a clinical trial of its liquid biopsy test have been accepted for presentation at the American Society of Clinical Oncology (‘ASCO’) Annual Meeting. The abstract will be released on 17 May, ahead of the conference which takes place on 2-6 June, 2017.
The poster presentation will cover results of a study evaluating the Copy Number Instability (CNI)-score as a prognostic test in head and neck cancer. The study compares the Chronix CNI-score test’s accuracy as a predictor of time to progression with the current method based on clinical parameters (e.g. staging, invasion of lymph nodes). Predicted time to progression is an important factor that that can aid the therapeutic decision (i.e. adjuvant treatment) in this condition.